ImaginAb Inc., a clinical-stage immuno-oncology imaging company, today announces it has enrolled its first patient for the Phase II clinical trial of its lead product CD8 tracer, 89Zr-Df-IAB22M2C, at the O’Neal Comprehensive Cancer Center at the University of...
BMN 307 Represents a Potential 3rd PKU Treatment Option in BioMarin’s PKU Franchise 2nd Gene Therapy Program in Product Pipeline BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a pioneer in treatments for rare disease Phenylketonuria (PKU) and in gene therapies,...
In the digital age, Search Engine Optimization (SEO) provides companies with ample opportunity to increase business. If a business is not utilizing SEO, they are doing themselves a disservice. For example, for a clinical trials recruitment agency, SEO provides the...
FibroGen, Inc. (FGEN) today announced first patient dosed in the company’s Phase 2 clinical study of roxadustat, a first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for the treatment of chemotherapy-induced anemia (CIA) in cancer patients...
Scientists at the University of Strathclyde researching a system to measure and monitor blood chemistry levels in premature and sick babies through their skin Scientists at the University of Strathclyde are researching a system to measure and monitor blood chemistry...
Aldeyra Therapeutics, Inc. (ALDX) (Aldeyra) today announced that it will host an ePoster presentation and discussion of the company’s ALLEVIATE Phase 3 clinical trial of reproxalap in patients with allergic conjunctivitis at the American Academy of Ophthalmology 2019...
Email
Text